


## Stambomycine

### An innovation that brings to you...

- ✓ Macrolides produced from *Streptomyces ambofaciens* bacteria
- ✓ Efficient against Gram + bacteria
- ✓ Antiproliferative activity



### How does it work?

The study of one *Streptomyces ambofaciens* bacteria strain has enabled the identification and characterization of a new macrolide complex: stambomycines. **They exhibit antibacteria activities against Gram + bacteria**, except for *Mycobacterium smegmatis*. However, they display no activity against Gram - bacteria and *Candida albicans* yeast or *Aspergillus fumigatus* and *Fusarium oxysporum* filamentous fungi.

Stambomycines also show very promising antiproliferative activities **against the tested tumor cell lines** (HT29, MCF7, H460 et PC3). Results from cytotoxicity tests are also very favorable, since they are not more toxic than the reference molecule, the doxorubicine, which is one of the main substances used in anticancer chemotherapy. Analyses are currently being performed to determine the antiproliferative action mechanism of these molecules.

### What is it for?

- ✓ Antibiotics
- ✓ Antitumor treatments
- ✓ Agrifood components, agricultural products
- ✓ Industrial decontaminant, disinfectant

### Innovation availability

- ✓ Patent WO 2011/009938
- ✓ Collaboration sought: Licensing for the commercialization of new molecules
- ✓ Readiness Level: Synthesis process at the laboratory scale. In vitro tests.

#### Your Contact :

**Daniel Kirchherr**  
Development officer  
Tel : 07 76 16 66 90  
Mail : daniel.kirchherr@sattge.fr